#1 Clinical Trials Search in Europe

Brexpiprazole

Brexpiprazole, also known by its brand name Rexulti, is an atypical antipsychotic medication that has been the subject of several clinical trials for various mental health conditions. These trials aim to evaluate its efficacy, safety, and tolerability in treating disorders such as schizophrenia, major depressive disorder, bipolar disorder, and others. This article summarizes key findings from recent clinical trials investigating the use of brexpiprazole.

Table of Contents

What is Brexpiprazole?

Brexpiprazole, also known by its brand name Rexulti, is a medication that belongs to a class of drugs called atypical antipsychotics. It is a relatively new drug that has been developed to treat various mental health conditions[1]. Brexpiprazole is designed to work on specific chemical messengers in the brain, helping to balance brain activity and improve symptoms associated with certain mental health disorders.

What Conditions Does Brexpiprazole Treat?

Brexpiprazole is used to treat several mental health conditions, including:

  • Schizophrenia: A severe mental disorder characterized by distorted thinking, hallucinations, and altered perceptions of reality[1].
  • Major Depressive Disorder (MDD): As an add-on treatment to antidepressants for adults with MDD who haven’t responded well to antidepressant therapy alone[1][2].
  • Agitation associated with Dementia of the Alzheimer’s Type: Research is ongoing to evaluate its effectiveness in treating agitation in people with Alzheimer’s disease[3].
  • Bipolar Depression: Studies are being conducted to assess its potential in treating depressive episodes in bipolar disorder[4].
  • Borderline Personality Disorder (BPD): Clinical trials are investigating its use in managing symptoms of BPD[5].
  • Post-Traumatic Stress Disorder (PTSD): Research is exploring its potential benefits for individuals with PTSD[6].

How Does Brexpiprazole Work?

Brexpiprazole works by affecting the activity of certain neurotransmitters (chemical messengers) in the brain, primarily dopamine and serotonin. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, while also being an antagonist at serotonin 5-HT2A receptors[6]. In simpler terms, this means that Brexpiprazole can help balance the activity of these important brain chemicals, which play crucial roles in mood regulation, thinking processes, and behavior.

Dosage and Administration

Brexpiprazole is typically taken orally as a tablet. The dosage can vary depending on the condition being treated and individual patient factors. Here are some general guidelines:

  • For schizophrenia: The recommended starting dose is usually 1 mg once daily, which may be increased to 2-4 mg daily based on the patient’s response and tolerability[1].
  • For major depressive disorder: As an add-on treatment, the starting dose is often 0.5 mg or 1 mg once daily, which may be increased to 2 mg daily[1].
  • For other conditions: Dosages may vary and should be determined by a healthcare provider.

It’s crucial to take Brexpiprazole exactly as prescribed by your doctor. Do not change your dose or stop taking the medication without consulting your healthcare provider.

Efficacy of Brexpiprazole

Clinical trials have shown promising results for Brexpiprazole in treating various mental health conditions:

  • In schizophrenia, it has been found to reduce symptoms such as hallucinations, delusions, and disorganized thinking[1].
  • For major depressive disorder, when used as an add-on treatment, it has shown improvements in depressive symptoms and overall functioning[2].
  • Ongoing research is evaluating its effectiveness in other conditions like bipolar depression, where it may help improve mood, cognitive function, and quality of life[4].

Potential Side Effects

Like all medications, Brexpiprazole can cause side effects. Common side effects may include:

  • Weight gain
  • Akathisia (a feeling of inner restlessness)
  • Headache
  • Drowsiness or fatigue
  • Nausea or constipation
  • Dizziness

More serious side effects, though less common, can include changes in metabolism, increased blood sugar levels, and movement disorders. It’s important to discuss any side effects with your healthcare provider[7].

Special Considerations

There are some important factors to consider when taking Brexpiprazole:

  • Elderly patients with dementia-related psychosis: Brexpiprazole may increase the risk of death in elderly patients with dementia-related psychosis.
  • Suicidal thoughts: There may be an increased risk of suicidal thoughts, especially in young adults. Close monitoring is important, especially when starting treatment or changing doses[7].
  • Pregnancy and breastfeeding: The safety of Brexpiprazole during pregnancy and breastfeeding is not well established. Discuss the risks and benefits with your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
  • Drug interactions: Brexpiprazole can interact with other medications. Always inform your healthcare provider about all medications you are taking.

Ongoing Research

Researchers continue to study Brexpiprazole to better understand its potential benefits and risks. Current areas of investigation include:

  • Its effectiveness in treating agitation associated with Alzheimer’s disease[3].
  • Its potential use in bipolar depression, focusing on improvements in mood, cognitive function, and overall quality of life[4].
  • Its efficacy and safety in treating borderline personality disorder[5].
  • Its potential benefits for individuals with post-traumatic stress disorder[6].

These ongoing studies aim to expand our understanding of Brexpiprazole and potentially broaden its therapeutic applications in the future.

Condition Key Findings Dosage Range Primary Outcome Measures
Schizophrenia Efficacious in treating symptoms; improved cognitive function observed 1-4 mg/day Positive and Negative Syndrome Scale (PANSS) scores
Major Depressive Disorder Effective as adjunctive therapy; improved depressive symptoms 0.5-3 mg/day Montgomery-Åsberg Depression Rating Scale (MADRS) scores
Bipolar Disorder Potential efficacy in bipolar depression; ongoing studies 1-3 mg/day MADRS scores, cognitive function assessments
Post-Traumatic Stress Disorder Under investigation; potential impact on PTSD symptoms 2-4 mg/day CAPS-5 scores, pupil diameter measurements
Borderline Personality Disorder Preliminary studies show potential benefits; further research needed 1-2 mg/day Zanarini Rating Scale for Borderline Personality Disorder

FAQ

  • What conditions is brexpiprazole being studied for in clinical trials? Brexpiprazole is being studied for various mental health conditions, including schizophrenia, major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder (PTSD), borderline personality disorder, and agitation associated with dementia of the Alzheimer's type.
  • What are some common dosages of brexpiprazole used in clinical trials? Dosages vary depending on the condition being treated. For schizophrenia, doses typically range from 1-4 mg per day. For MDD, doses are usually between 0.5-3 mg per day as an adjunctive therapy. Clinical trials often start with lower doses and titrate up based on patient response and tolerability.
  • What are some potential side effects of brexpiprazole observed in clinical trials? Common side effects reported in clinical trials include weight gain, akathisia (restlessness), and extrapyramidal symptoms. Trials also monitor for changes in metabolic parameters, such as blood glucose and lipid levels. The severity and frequency of side effects are typically assessed using standardized scales.
  • How is the efficacy of brexpiprazole measured in clinical trials? Efficacy is often measured using standardized rating scales specific to the condition being studied. For example, the Montgomery-Åsberg Depression Rating Scale (MADRS) is used for depression, while the Positive and Negative Syndrome Scale (PANSS) may be used for schizophrenia. Researchers also assess changes in cognitive function, quality of life, and overall functioning.
  • Are there any ongoing long-term studies on brexpiprazole? Yes, there are ongoing long-term studies to evaluate the safety and efficacy of brexpiprazole over extended periods. These studies aim to assess the medication's effects on symptoms, cognitive function, and overall patient well-being over time, as well as to monitor for any potential long-term side effects or changes in efficacy.

Ongoing Clinical Trials on Brexpiprazole

  • A Study Testing Brexpiprazole Given Once Weekly to Treat Sudden Worsening of Symptoms in Patients with Schizophrenia

    Recruiting

    1 1 1
    Investigated drugs:
    Romania

  • Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

Glossary

  • Brexpiprazole: An atypical antipsychotic medication used to treat various mental health conditions, also known by the brand name Rexulti.
  • Atypical antipsychotic: A newer class of antipsychotic medications that generally have fewer side effects than older, typical antipsychotics.
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities.
  • Bipolar Disorder: A mental health condition characterized by alternating periods of depression and mania or hypomania.
  • Schizophrenia: A chronic mental disorder that affects a person's ability to think, feel, and behave clearly.
  • Post-Traumatic Stress Disorder (PTSD): A mental health condition triggered by experiencing or witnessing a terrifying event.
  • Borderline Personality Disorder (BPD): A mental health disorder characterized by unstable moods, behavior, and relationships.
  • Adjunctive therapy: Additional treatment used together with the primary treatment to improve outcomes.
  • Titration: The process of gradually adjusting the dose of a medication to find the optimal balance between efficacy and side effects.
  • Montgomery-Åsberg Depression Rating Scale (MADRS): A standardized questionnaire used to measure the severity of depressive episodes in patients with mood disorders.
  • Young Mania Rating Scale (YMRS): A rating scale used to evaluate manic symptoms in patients with bipolar disorder.
  • Clinical Global Impression (CGI) Scale: A tool used by healthcare professionals to assess the overall severity and improvement of a patient's condition in clinical trials.
  • Akathisia: A movement disorder characterized by a feeling of inner restlessness and inability to stay still.
  • Extrapyramidal symptoms: A group of side effects that can occur with antipsychotic medications, including muscle stiffness, tremors, and involuntary movements.
  • C-reactive protein (CRP): A protein produced by the liver in response to inflammation, often used as a marker of inflammation in the body.

References

  1. https://clinicaltrials.gov/study/NCT04641780
  2. https://clinicaltrials.gov/study/NCT04830215
  3. https://clinicaltrials.gov/study/NCT03594123
  4. https://clinicaltrials.gov/study/NCT04569448
  5. https://clinicaltrials.gov/study/NCT03418675
  6. https://clinicaltrials.gov/study/NCT02934932
  7. https://clinicaltrials.gov/study/NCT04186403